Cannabis
Emerald Health Therapeutics Comments on Board Resignation
Vancouver, British Columbia–(Newsfile Corp. – August 11, 2021) – Further to its press release of August 6th, Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald” or the “Company”) provides additional details regarding the resignation of Dr. Avtar Dhillon as director and executive chairman. On August 5th the Company became aware that Dr. Avtar Dhillon had been arrested in the United States and charged with violations of US federal securities laws with respect to trading in certain US companies unrelated to Emerald. On August 6th Dr. Dhillon resigned from all roles with the Company, as previously announced. On August 9th the Securities and Exchange Commission announced certain additional charges against Dr. Dhillon and certain other individuals not related to Emerald.
None of the allegations in the charges against Dr. Dhillon or any of the other individuals charged mention any improper trading of Emerald securities and the Company is not able to comment on the veracity of any of the allegations made against Dr. Dhillon or any of the other individuals charged. The Company is not aware of any improper trading in Emerald securities and no allegations have been made against any other person associated with Emerald, including any of its officers or other directors. The Company and its legal counsel are currently considering whether there are any additional steps they can take in the best interests of the Company and its shareholders.
About Emerald Health Therapeutics, Inc.
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on science-based innovation and product excellence.
Please visit www.emeraldhealth.ca for more information or contact:
Jenn Hepburn, Chief Financial Officer
1(800) 757 3536 Ext. #5
Emerald Investor Relations
(800) 757 3536 Ext. #5
[email protected]
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92850
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis3 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE3 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Humboldt3 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace